SCIEX partnership seeks to speed drug development
Photo | Google Maps
SCIEX in Framingham.
Framingham biotech company SCIEX announced a supply relationship with RedShiftBio, a Burlington firm specializing in analytical instrumentation for therapeutic drugs.
The goal of the partnership is to help more biopharmaceutical labs access the critical data necessary to close the pharmaceutical drug developability gap, according to the Nov. 16 press release.
Through the supply agreement, SCIEX will resell the AQS3 pro from RedShiftBio throughout the U.S. The AQS3 pro’s technology provides accurate analysis of biomolecules’ higher order structure through the implementation of a unique microfluidic system and a quantum cascade laser, per SCIEX.
“Together, these complementary solutions will help customers optimize their drug development workflows and ultimately make better drugs, faster,” said Julien Bradley, CEO of RedShiftBio, in a written statement about the new partnership.
WBJ Web Partners
Most Recent
Most Recent
0 Comments